GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Notes Receivable

CAMP (Camp4 Therapeutics) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Notes Receivable?

Camp4 Therapeutics's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Camp4 Therapeutics Notes Receivable Historical Data

The historical data trend for Camp4 Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Notes Receivable Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Notes Receivable
- - -

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial - - - - -

Camp4 Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Camp4 Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Camp4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.